WeVote
Log In

Bill

Bill

SB 3221

CONTROLLED SUB-XYLAZINE

104th Regular Session Introduced by Julie Morrison

Illinois law would regulate sub-xylazine with stricter controls, reporting, penalties, and enforcement to curb its illicit production, distribution, and adulteration.

Referred to Assignments
0
WeVote Research Nonpartisan
Bill Summary · SB 3221

Overview

SB 3221 (104th Illinois General Assembly) titled “Controlled Sub-Xylazine” aims to address the regulation, control, and illegal distribution of the drug sub-xylazine by enhancing reporting, scheduling, and enforcement measures. The bill adds Sub-Xylazine to regulatory controls to curb its misuse, trafficking, and associated public health risks. Co-sponsor: Julie Morrison.

Purpose and intent

  • Reduce illicit production, distribution, and use of Sub-Xylazine.
  • Strengthen public health and safety protections by creating stricter regulatory oversight and enforcement tools.
  • Align Illinois efforts with broader public health responses to synthetic and adulterant drugs.

Key provisions and changes

  • Classification and scheduling: Establishes Sub-Xylazine within a regulated framework (specific scheduling status and control requirements, including penalties for unauthorized possession, distribution, or manufacture).
  • Penalties and enforcement: Increases penalties for illegal possession, sale, or distribution of Sub-Xylazine; expands law enforcement authority to seize, investigate, and prosecute offenses involving Sub-Xylazine.
  • Reporting and recordkeeping: Imposes mandatory reporting, inventory controls, and recordkeeping for manufacturers, distributors, and retailers handling Sub-Xylazine.
  • Combatting adulteration: Addresses Sub-Xylazine as an adulterant or adulterant component in illicit drug supply, enabling law enforcement and public health responses to adulterated substances.
  • Regulatory coordination: Requires coordination among state agencies (public health, law enforcement, and regulatory bodies) to implement and enforce the act; may establish rulemaking or guidance processes.
  • Public health provisions: Supports monitoring, data collection, and potential funding or resource allocation to address Sub-Xylazine-related health risks, including prevention and treatment considerations.
  • Effective date and transition: Specifies when provisions take effect and any phased implementation or regulatory actions needed to bring the bill into force.

Who is affected

  • Manufacturers, distributors, wholesalers, and retailers handling Sub-Xylazine will face new regulatory requirements (reporting, recordkeeping, licensing, and penalties).
  • Law enforcement and state regulatory agencies will gain expanded powers and duties to investigate, seize, and prosecute Sub-Xylazine-related offenses.
  • Public health and healthcare systems may experience enhanced surveillance, data collection, and potential funding for prevention and treatment related to Sub-Xylazine misuse.
  • Individuals involved in the illicit production or distribution of Sub-Xylazine could face increased penalties.

Procedural and timeline aspects

  • The bill outlines scheduling and enforcement timelines, including when the new controls become effective and any interim regulatory actions or rulemaking processes.
  • May require administrative rules or guidance from relevant state agencies to operationalize the provisions.
  • Likely includes enforcement milestones tied to licensing, reporting, and inventory controls.

Note: This summary is based on the bill’s title and sponsor information. For precise language, exact scheduling status, penalties, and implementation timelines, please refer to the official text of SB 3221 and any amendments adopted by the Illinois General Assembly.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.